The U.S. Food and Drug Administration has approved KERENDIA (finerenone) for adults with chronic kidney disease associated with type 1 diabetes.
The Centers for Disease Control and Prevention is merging its Influenza Division with the Coronavirus and Other Respiratory Diseases Division to create the Influenza and Respiratory Viruses Division.
The Centers for Disease Control and Prevention has issues its recommendations for use of the seasonal 2026-2027 influenza (flu) vaccines.
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets to treat dermatomyositis in adults.
Updated COVID-19 vaccines from Moderna, Novavax-Sanofi and Pfizer-BioNTech have been approved by the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has licensed Ezplaz Freeze Dried Plasma (FDP), the first freeze-dried plasma product licensed for use in the U.S.
A Phase III trial evaluating adjuvant treatment with intismeran autogene in combination with KEYTRUDA (pembrolizumab) showed positive results in treating patients with completely resected stage IIB-IV melanoma.
The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults.
A new study has found infants are far more vulnerable than older children to severe illness from viruses such as influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2.
The U.S. Food and Drug Administration has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
Researchers have developed an experimental therapeutic nasal DNA vaccine for tuberculosis.
Scientists have developed a new HIV vaccine that has the potential to protect humans from developing HIV infection and AIDS.